Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C9H11FN2O5 |
Molecular Weight | 246.1924 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H]1O[C@H]([C@H](O)[C@@H]1O)N2C=C(F)C(=O)NC2=O
InChI
InChIKey=ZWAOHEXOSAUJHY-ZIYNGMLESA-N
InChI=1S/C9H11FN2O5/c1-3-5(13)6(14)8(17-3)12-2-4(10)7(15)11-9(12)16/h2-3,5-6,8,13-14H,1H3,(H,11,15,16)/t3-,5-,6-,8-/m1/s1
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/6230419
Sources: http://www.ncbi.nlm.nih.gov/pubmed/6230419
Doxifluridine is a 5-fluorouracil prodrug that is being tested for the treatment of cancer. The cleavage into 5-fluorouracil occurs enzymatically via a nucleoside phosphorylase. Thus, doxifluridine is not active by itself and its antitumor activity is related to its metabolic conversion into 5-fluorouracil. Doxifluridine has neurotoxic adverse effects.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P23919 Gene ID: 1841.0 Gene Symbol: DTYMK Target Organism: Homo sapiens (Human) |
|||
Target ID: GO:0090592 |
|||
Target ID: GO:0009299 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Doxifluridine (5'-dFUrd) in patients with advanced colorectal carcinoma. A phase II study. | 1985 |
|
Neurological manifestations in a phase 2 study of 13 patients treated with doxyfluridine. | 1985 Aug |
|
Phase II clinical evaluation of doxifluridine. | 1986 Jun |
|
Transfection of thymidine phosphorylase cDNA to human hepatocellular carcinoma cells enhances sensitivity to fluoropyrimidine but augments endothelial cell migration. | 2005 Aug |
|
Gene expression analysis using human cancer xenografts to identify novel predictive marker genes for the efficacy of 5-fluorouracil-based drugs. | 2006 Jun |
|
Unpredicted severe toxicity after 5-fluorouracil treatment due to dihydropyrimidine dehydrogenase deficiency. | 2006 Mar |
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/23449357
460-600mg/m2/day per oral (Gastric cancer)
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/6221792
The cytotoxicity of Doxifluridine was determined in several cultured human tumor lines including tumors of the breast (47-DN, MCF-7), the colon (HCT-8), and the pancreas (Coto-357), as well as an osteosarcoma (MG-63) and a leukemia (HL-60). In vitro clonogenic assays were used to measure cytotoxicity following a 3hr drug exposure. Doxifluridine was less potent than was 5-fluorouracil or 5-fluoro-2'-deoxyuridine in all cells examined, exhibiting its best activity against the 47-DN [concentration that prevented 50% clonal growth compared to untreated control (LD50) = 32 uM] and MCF-7 (LD50= 35 uM) breast carcinomas and MG63 osteosarcoma (LD50 = 41 uM). Intermediate activity was observed against HCT-8 (LD50 = 200 uM)and Colo-357 (LD50 = 150 uM) gastrointestinal tumors. Doxifluridine had very poor activity against the HL-60 leukemia (LD50 = 470 uM).
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1557
Created by
admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB12947
Created by
admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
|
PRIMARY | |||
|
Doxifluridine
Created by
admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
|
PRIMARY | |||
|
758890
Created by
admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
|
PRIMARY | |||
|
DTXSID2022967
Created by
admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
|
PRIMARY | |||
|
SUB06389MIG
Created by
admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
|
PRIMARY | |||
|
4913
Created by
admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
|
PRIMARY | |||
|
C025034
Created by
admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
|
PRIMARY | |||
|
C978
Created by
admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
|
PRIMARY | |||
|
1090728
Created by
admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
|
PRIMARY | |||
|
m4755
Created by
admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
|
PRIMARY | Merck Index | ||
|
3094-09-5
Created by
admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
|
PRIMARY | |||
|
18343
Created by
admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
|
PRIMARY | |||
|
221-440-1
Created by
admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
|
PRIMARY | |||
|
V1JK16Y2JP
Created by
admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
|
PRIMARY | |||
|
CHEMBL1130
Created by
admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
|
PRIMARY | |||
|
31521
Created by
admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
|
PRIMARY | |||
|
958
Created by
admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
|
PRIMARY | |||
|
100000080814
Created by
admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (METABOLITE)